SHINGLES PRESENTATION

Shingles can be painful and can lead to serious and long-lasting complications1,2,*

  • *

    SHINGRIX is not indicated for the prevention of herpes zoster-related complications.3

Picture of shingles on back

Shingles presentation

  • A unilateral, vesicular rash1
  • Causes burning, stabbing, aching, and shock-like pain1
  • Some severe cases have been described as worse than labor pain4

SHINGLES COMPLICATIONS*

  • *

    SHINGRIX is not indicated for the prevention of herpes zoster-related complications.3

Postherpetic neuralgia (PHN) graphic

Postherpetic neuralgia (PHN)

  • Characterized by long-lasting nerve pain that persists for months (≥90 days), but can sometimes last years1
  • The nature of PHN pain varies from mild to excruciating—approximately half of patients describe their pain as “horrible”1
  • Between 6% and 45% of immunocompromised (IC) patients with herpes zoster developed PHN5,†

 

†Based on data from a systematic review involving individuals with hematopoietic stem cell transplant, hematologic malignancies, solid tumors, HIV, or solid organ transplants.5

Picture of shingles on face

Herpes zoster ophthalmicus

  • Can lead to ophthalmic complications and, in rare cases, vision loss1
Picture of shingles on neck

Disseminated herpes zoster

  • Widespread rash across multiple dermatomes5
  • Most likely to occur in patients who are IC5,6
  • Median occurrence of 3% in patients who are IC5,†
  • Is a marker for varicella zoster virus viremia that can seed the lungs, liver, gut, and brain, and cause pneumonia, hepatitis, encephalitis, and disseminated intravascular coagulopathy1

 

†Based on data from a systematic review involving individuals with hematopoietic stem cell transplant, hematologic malignancies, solid tumors, human immunodeficiency virus, or solid organ transplants.5

You may also be interested in:

Efficacy

Learn about efficacy data in immunocompromised patients aged 18 years and older.

SEE DATA

Safety Profile

Learn about the safety profile of SHINGRIX in immunocompromised patients aged 18 years and older.

SAFETY INFO

Reconstitution & Administration

See how you and your staff can reconstitute SHINGRIX in 4 steps.

DISCOVER RECONSTITUTION

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
  2. Kawai K, Gebremeskel BG, Acosta CJ. BMJ Open. 2014;4(6):e004833.
  3. Prescribing Information for SHINGRIX.
  4. Katz J, Melzack R. Surg Clin North Am. 1999;79(2):231-252.
  5. McKay SL, Guo A, Pergam S, Dooling K. Clin Infect Dis. 2020;71(7):e125-e134.
  6. Anderson T. Zoster vaccines session: burden of herpes zoster in immunocompromised adults. Presented at: ACIP Meeting; June 25, 2021.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET